Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: Sources and consequences

Clinical Nephrology

Volumn 68, Issue 1, 2007, Pages 1-9

  Yilmaz, M I ^a   Carrero, J J ^a   Axelsson, J ^a   Lindholm, B ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic kidney disease; Low grade inflammation; Renal replacement therapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CYTOKINE; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; OXIDIZING AGENT; PARA CRESOL; PENTOXIFYLLINE; PLASMIN; PLASMIN INHIBITOR; REACTIVE OXYGEN METABOLITE;

ALBUMIN BLOOD LEVEL; BACTERIAL INFECTION; BODY COMPOSITION; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HEMODIALYSIS PATIENT; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOCYTE COUNT; MONONUCLEAR CELL; MUSCLE ATROPHY; NEPHRITIS; NEUTROPHIL COUNT; NONHUMAN; PATHOGENESIS; PROTEIN CALORIE MALNUTRITION; PROTEIN LOCALIZATION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; RISK REDUCTION; TUBERCULOSIS; UREMIA;

EID: 34447255169     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68001     Document Type: Review

References (85)

1. Ando M, Shibuya A, Tsuchiya K, Akiba T, Nitta K. Reduced capacity of mononuclear cells to synthesize cytokines against an inflammatory stimulus in uremic patients. Nephron Clin Praet. 2006a; 104: c113-c119.
2. Ando M, Shibuya A, Tsuchiya K, Akiba T, Nitta K. Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int. 2006b; 70: 358-362.
3. Avesani CM, Carrero JJ, Axelsson J, Quresht AR, Lindholm B, Stenvinkel P. Inflammation and wasting in chronic kidney disease: parsers in crime. Kidney Int. 2006; 104: S8-S13.
4. Axelsson J, Qureshi AR, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, Lindholm B, Cederholm T, Stenvinkel P. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr. 2004; 80: 1222-1229.
5. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006; 69: 1081-1087.
6. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in murine model. J Immunol. 1993; 150: 2007-2017.
7. Bradbury B, Krishnan M, Critchlow C. Correlation of C-reactive protein (CRP) levels and markers of disease severity in hemodialysis (HD) patients. J Am Soc Nephrol. 2006; 17 Nov: F-PO603.
8. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol. 2005; 78: 819-835.
9. Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension. 2005; 45: 1042-1049.
10. Cohen G, Rudnicki M, Deicher R, Hörl WH. Immunglobulin light chains modulate polymorphonuclear leucocyte apoptosis. Eur J Clin Invest. 2003; 33: 669-676.
11. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int. 2003; Suppl 87: S24-31.
12. Craig RG, Spittle MA, Levin NM. Importance of peridontal disease in the kidney patient. Blood Purif. 2002; 20: 113-119.
13. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444: 881-887.
14. Diamond JR, Karnovsky MJ. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int. 1991; 31: S29-34.
15. Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006; 48: 926-934.
16. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katpodis KP, Tselepis A, Siamopoulos KC, Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006; 48: 752-760.
17. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin J-M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002; 62: 1417-1422.
18. Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C. Long-term CAPD patients are volume-expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant. 2001; 16: 1459-1464.
19. Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res. 2002; 90: 2-4.
20. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United States dialysis population 1991-1999. J Am Soc Nephrol. 2004; 15: 1038-1045.
21. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9: S16-23.
22. Glorieux G, Helling R, Henle T, Brunet P, Deppish R, Lameire N, Vanholder R. In vitro evidence for immune activation effect of specific AGE structures in uremia. Kidney Int. 2004; 66: 1873-1880.
23. Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumonia infection - long-term predictors of cardiovascular disease survival in patients on peritoneal dialysis. Nephrol Dial Transplant. 2001; 16: 809-815.
24. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006; 47: 139-148.
25. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant. 1999; 14: 1956-1960.
26. Jabs WJ, Lögering BA, Gerke P, Kreft B, Wolber EM, Klinger MHF, Frieke L, Steinhoff J. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003; 33: 152-161.
27. Johansen KI, Kaysen GA, Young BS, Hung AM, da Silva M, Chertow GM. Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr. 2003; 77: 842-846.
28. Kaizu Y, Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K, Kumagai H. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis. 2003; 42: 295-302.
29. Kaysen GA, Dublin JA, Müller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int. 2000; 58: 346-352.
30. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996; 144: 537-547.
31. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004; 43: 244-253.
32. Lane DA, Ireland H, Knight I, Wolff S, Kyle P, Curtis JR. The significance of fibrinogen derivates in plasma in human renal failure. Br J Haematol. 1984; 56: 251-260.
33. Li PK, Ghow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized controlled study. Ann Intern Med. 2003; 139: 105-112.
34. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tasi TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol. 2002; 13: 2916-2929.
35. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005; 68: 766-772.
36. Muntner P, Hamm L, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in pateints with chronic kidney disease. Ann Intern Med. 2004; 140: 9-17.
37. Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, Matsui A. C-reactive protein frequently localizes in the kidney in glomerular disease. Clin Nephrol. 2001; 55: 365-370.
38. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant. 1998; 18: 387-394.
39. Oberg BP, Mcmenamin E, Lucas FL, Mcmonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalance of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004; 65: 1009-1016.
40. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang JW. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation. 2001; 103: 2531-2534.
41. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165-2168.
42. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine. 1990; 2: 416-422.
43. Qureshi A, Snaedal-Jonsdottir S, Heimburger O, Lindholm B, Alvestrand A, Stenvinkel P, Barany P. Serial measurements of C-reactive protein (CRP) predict outcome better than a single value in hemodialysis (HD) patients. J Am Soc Nephrol. 2006; 17: 27A.
44. Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Takashi Akiba T, Jadoul M, Ginsberg N, Keen M, Port FK, Mukherjee D, Saran R. Peripheral arterial disease in patients with end-stage renal disease. Observations from the dialysis outcomes and practice patterns study (DOPPS). Circulation. 2006; 114: 1914-1922.
45. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-979.
46. Sarnak MJ, Jaber BL. Mortality causes by sepsis in pateints with end-stage renal disease compared to the general population. Kidney Int. 2000; 58. 1758-1764.
47. Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS. Serum C-reactive protein and leptin as predictors of kidney disease in the modification of diet in renal disease study. Kidney Int. 2002; 62: 2208-2215.
48. Schepers E, Meert N, Glorieux G, Goeman J, van der Eycken J, Vanholder R. P-cresylsulphate, the main product in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2006; 22: 592-596.
49. Sela S, Shurtz-Swiriski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Sckolnik G, Geron R, Kristal B. Primed peripheral polymorponuclear leucocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2431-2438.
50. Sezer S, Ibis A, Ozdemir BH, Ozdemir FN, Kulah E, Boyacioglu S, Haberal M. Association of Helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc. 2004; 36: 47-49.
51. Shlipak MG, Fried LE Crump C, Bleyer AJ, Manolio TA, Tracy RR, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107: 87-92.
52. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L. Cystatin C and inflammatory markers in the ambulatory elderly. Am J Med. 2005; 118: e25-e31.
53. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006; 11: 36-41.
54. Stenvinkel P, Andersson A, Wang T, Lindholm B, Bergström J, Palmblad J, Heimbürger O, Cederholm T. Do ACE inhibitors suppress tumor necrosis factor-a production in advanced chronic renal failure? J Int Med. 1999; 246: 503-507.
55. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int. Suppl. 2002a; 80: 103-108.
56. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to Clamydia pneumoniae seropositivity. Am J Kidney Dis. 2002b; 39: 274-282.
57. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M. IL- 10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 2005; 67: 1216-1233.
58. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif. 2005; 23: 72-78.
59. Stenvinkel P, Lindholm B, Heimbürger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dial. 2004; 17: 505-515.
60. Stenvinkel P, Lindholm B, Lönnqvist F, Katzarski K, Heimbürger O. Increases in serum leptin during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol. 2000; 11: 1303-1309.
61. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Lorenzo L, Zoccali C. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int. 2002c; 62: 1791-1798.
62. Stuveling EM, Hillege HL, Bakker SJL, Gans ROB, de Jong PE, de Zeeuw D. C-reactive protein is associated with renal function abnormalities in a nondiabetic population. Kidney Int. 2003; 63: 654-661.
63. Suliman M, Heimbürger O, Barany P, Anderstam B, Pecoits-Filho R, Ayala ER, Fehrman I, Lindholm B, Stenvinkel P. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003; 14: 1614-1622.
64. Tracey KJ. The inflammatory reflex. Nature. 2002; 420: 853-859.
65. Tracey KJ. Fat meets the cholinergic antiinflammatory pathway. JEM. 2005; 202: 1017-1021.
66. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997; 17: 1121-1127.
67. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-canse and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005; 16 Suppl 1: S83-88.
68. van Tellingen A, Grooteman MPC, Sehoorl M, Bartels PCM, Schoorl M, van der Ploeg T, ter Wee P, Nubé MJ. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int. 2002; 62: 632-638.
69. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lamiere N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20: 1048-1056.
70. Varagunam M, Finney H, Trevitt R, Sharpies E, Mc-Closkey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis. 2004; 43: 502-507.
71. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106: 1439-1441.
72. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, Mickle DA. C-reactive protein activates the nuclear factor-κB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg. 2003; 126: 1886-1891.
73. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109: 2058-2067.
74. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105: 1890-1896.
75. Wang AY, Woo J, Wai Kei C, Wang M, Man Sei M, Lui S-F. Li PK-T, Sanderson JE. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol. 2003a; 14: 1871-1879.
76. Wang AY Sea MM, Tang N, Sanderson JE, Lui SF, Li PK, Woo J. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol. 2004; 15: 3134-3143.
77. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003b; 107: 1783-1790.
78. Ward RA, McLeish KR. Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol. 1995; 5: 1697-1702.
79. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808.
80. Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative study group. Kidney Int. 1998; 54: 193-202.
81. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115: 1111-1119.
82. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476.
83. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflanmmtion enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.
84. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapiarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M. Fibrinogen, mortality and incident cardiovascular complicatious in end-stage renal failure. J Intern M ed. 2003; 254: 132-139.
85. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol. 2006; 17: S169-S173.